Literature DB >> 17201414

Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis.

M Paul Gleeson1.   

Abstract

In-silico plasma protein binding (PPB) models have been generated on human and rat in-house datasets, and on a human dataset sourced from the literature. From the results reported herein, it is apparent that models built on datasets relevant to the chemotypes under investigation in lead optimization programs will perform considerably better in this role than those generated on diverse compounds sourced from the literature. The in-house human and rat partial least-squares regression (PLS) models have cross-validated q2 values of 0.53 and 0.42 on the training sets, respectively. On the independent test and validation sets, they display similar predictive ability, with logK prediction errors of approximately 0.5 log units. This compares to approximately 0.25 log units variability expected for experiment. Given the considerable interspecies PPB differences, the prediction of PPB in one species using measurements in the other is no better than a prediction from an in-silico model generated on that species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17201414     DOI: 10.1021/jm060981b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models.

Authors:  M Paul Gleeson; Andrew M Davis; Kamaldeep K Chohan; Stuart W Paine; Scott Boyer; Claire L Gavaghan; Catrin Hasselgren Arnby; Cecilia Kankkonen; Nan Albertson
Journal:  J Comput Aided Mol Des       Date:  2007-11-22       Impact factor: 3.686

2.  Utility of Physicochemical Properties for the Prediction of Toxicological Outcomes: Takeda Perspective.

Authors:  Tomoya Yukawa; Russell Naven
Journal:  ACS Med Chem Lett       Date:  2020-01-29       Impact factor: 4.345

3.  QSAR models for the prediction of plasma protein binding.

Authors:  Taravat Ghafourian; Zeshan Amin
Journal:  Bioimpacts       Date:  2013-02-21

Review 4.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution.

Authors:  Estelle Yau; Andrés Olivares-Morales; Michael Gertz; Neil Parrott; Adam S Darwich; Leon Aarons; Kayode Ogungbenro
Journal:  AAPS J       Date:  2020-02-03       Impact factor: 4.009

6.  On quantitative relationships between drug-like compound lipophilicity and plasma free fraction in monkey and human.

Authors:  Sami S Zoghbi; Kacey B Anderson; Kimberly J Jenko; David A Luckenbaugh; Robert B Innis; Victor W Pike
Journal:  J Pharm Sci       Date:  2011-12-13       Impact factor: 3.534

Review 7.  The significance of acid/base properties in drug discovery.

Authors:  David T Manallack; Richard J Prankerd; Elizabeth Yuriev; Tudor I Oprea; David K Chalmers
Journal:  Chem Soc Rev       Date:  2013-01-21       Impact factor: 54.564

8.  Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Authors:  Chandrasekar Durairaj; Jaymin C Shah; Shruti Senapati; Uday B Kompella
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

9.  The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein binding.

Authors:  Xiang-Wei Zhu; Alexander Sedykh; Hao Zhu; Shu-Shen Liu; Alexander Tropsha
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

10.  Preferential uptake of the non steroid anti-inflammatory drug diclofenac into inflamed tissues after a single oral dose in rats.

Authors:  A Schweitzer; N Hasler-Nguyen; J Zijlstra
Journal:  BMC Pharmacol       Date:  2009-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.